Establishment of a Whole Animal HTS Novel Technology Platform for Anti-Bacterial Drug DiscoveryTuesday, 17 September 2013 at 11:00  Add to Calendar ▼2013-09-17 11:00:002013-09-17 12:00:00Europe/LondonEstablishment of a Whole Animal HTS Novel Technology Platform for Anti-Bacterial Drug DiscoveryAcademic Screening Workshop 2013 in Baltimore, MA, USABaltimore, MA, USASELECTBIOenquiries@selectbiosciences.comMelioidosis is a serious emerging endemic infectious disease caused by Burkholderia pseudomallei (B.p), a gram-negative pathogen. Septicemic Melioidosis has a mortality rate of 50% even with treatment. Like other gram-negative bacteria, B.p is resistant to a number of antibiotics and multi-drug resistant B.p is beginning to be encountered in hospitals. There is a clear medical need to develop new treatment options to manage this disease. We set out to establish a biologically relevant assay to screen for antibacterial compounds and to use this platform to identify novel compounds that can modulate the Melioidosis infection. We used Burkholderia thailandensis (a BSL-2 class organism) to infect Caenorhabditis elegans and set up a surrogate infection model of Melioidosis that we could run in a 384 microtitre plate and establish a whole animal HTS assay. We have optimized and validated this assay in a fluorescence-based format that can be run on our automated screening platforms. This assay has now been used to screen over 300,000 compounds from our small molecule library and we are in the process of characterizing the hits obtained and select compounds for further studies. |
Add to Calendar ▼2013-09-17 00:00:002013-09-18 00:00:00Europe/LondonAcademic Screening Workshop 2013Academic Screening Workshop 2013 in Baltimore, MA, USABaltimore, MA, USASELECTBIOenquiries@selectbiosciences.com
